Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

WASHINGTON — As part of next steps for the Janus Program, the Department of the Army has selected nine installations for consideration in which to site microreactor power plants, and the Defense ...

WASHINGTON — The Department of Army today announced the launch of the Janus Program, a next-generation nuclear power program that will deliver resilient, secure, and assured energy to support national ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

The Trump Administration says it will end a $7 billion program to help low-income households and communities get access to affordable solar energy. The move is part of President Trump's effort to ...

Tracy J. Wholf is a senior coordinating producer of climate and environmental coverage for CBS News and Stations, based in New York. The Environmental Protection Agency announced Thursday it is ...

For this week’s Open Questions column, Dhruv Khullar is filling in for Joshua Rothman. When David Fajgenbaum was a twenty-five-year-old medical student, at the University of Pennsylvania, he started ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...